Clin2
NCT04899687Possibly a fitRecruiting

Dextromethorphan for OCD and related anxiety conditions

Obsessive-Compulsive DisorderIllness Anxiety DisorderBody Dysmorphic DisordersSomatic Symptom Disorder

Treatments studied

Part of Mental health clinical trials.

This trial studies dextromethorphan, a medicine sometimes used for cough, to see if it can reduce symptoms in OCD and similar conditions. It may help people whose intrusive thoughts or related worries are still challenging despite current care.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
60 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You have a diagnosis of OCD, body dysmorphic disorder (BDD), illness anxiety disorder (IAD), or somatic symptom disorder (SSD)
  • You live in California
  • You can understand the study and sign informed consent
  • You do not currently have bipolar disorder or a psychotic disorder
  • You do not have moderate or severe substance use problems (or a history of severe substance use problems)
  • You are not pregnant and not nursing

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05783817Recruiting· Phase 2
MDMA-assisted therapy for OCD in adults

This trial tests whether MDMA plus cognitive behavioral therapy (CBT) can reduce OCD symptoms in adults who have tried standard OCD treatments before. You may be asked to pause certain medicines and follow specific diet/medication rules around the study session.

Palo Alto, California
NCT04539951Recruiting· Phase 2
Trial for newly treated obsessive-compulsive disorder

This phase 2 study tests an OCD treatment strategy for people who have not yet had OCD medications or recent OCD therapy. It aims to reduce OCD symptoms, especially for those with moderate-to-severe symptom levels.

Shanghai, Shanghai Municipality
NCT04131829Recruiting· Phase 1/Phase 2
Brain scan study to predict fluoxetine response in OCD

This study looks at how brain networks change before and after starting fluoxetine (an SSRI antidepressant) in people with obsessive-compulsive disorder (OCD). It also compares these brain scan patterns with people without OCD to help predict who may respond to treatment.

New Haven, Connecticut
NCT07347405Recruiting· Phase 1
Psilocybin Whole Mushroom for OCD Treatment

This trial tests a whole-mushroom version of psilocybin as a potential treatment for OCD that hasn't improved with standard therapies. Participants receive psilocybin in a controlled setting and are monitored closely for safety and changes in symptoms.

Tucson, Arizona
NCT06992999Not yet recruiting· Phase 1/Phase 2
Psilocybin for treating OCD

This study tests if a single dose of psilocybin, a psychedelic substance, can safely help people with obsessive-compulsive disorder (OCD) who have not responded well to standard treatments. If you have moderate to severe OCD and have tried at least one recommended treatment without success, you may be able to join.

Tucson, Arizona
NCT07701616Recruiting
Digital mindfulness therapy for obsessive-compulsive disorder

This study tests a smartphone-based mindfulness program to help people with obsessive-compulsive disorder (OCD) reduce their symptoms. If you have OCD and are between 12 and 65 years old, you may be able to join.

Changsha, Hunan

Hear when a new Obsessive-Compulsive Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.